NASDAQ:IMTX Immatics (IMTX) Stock Forecast, Price & News $9.85 +0.40 (+4.23%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$9.17▼$9.9350-Day Range$5.92▼$10.1052-Week Range$5.90▼$13.60Volume212,300 shsAverage Volume318,463 shsMarket Capitalization$755.20 millionP/E RatioN/ADividend YieldN/APrice Target$19.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immatics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.5% Upside$19.75 Price TargetShort InterestBearish8.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.53 out of 5 starsMedical Sector940th out of 1,010 stocksBiological Products, Except Diagnostic Industry156th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.75, Immatics has a forecasted upside of 100.5% from its current price of $9.85.Amount of Analyst CoverageImmatics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.05% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 28.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 3.3 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immatics this week, compared to 1 article on an average week.Search Interest11 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 29.05% of the stock of Immatics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.41) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immatics (NASDAQ:IMTX) StockImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Stock News HeadlinesMay 26, 2023 | finance.yahoo.comCompanies Like Immatics (NASDAQ:IMTX) Are In A Position To Invest In GrowthMay 23, 2023 | americanbankingnews.comHead-To-Head Analysis: Curis (NASDAQ:CRIS) & Immatics (NASDAQ:IMTX)May 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 21, 2023 | americanbankingnews.comSVB Leerink Comments on Immatics' Q2 2023 Earnings (NASDAQ:IMTX)May 18, 2023 | markets.businessinsider.comImmatics (IMTX) Gets a Buy from Mizuho SecuritiesMay 17, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Immatics (IMTX)May 16, 2023 | finance.yahoo.comImmatics Announces First Quarter 2023 Financial Results and Business UpdateMay 5, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Immatics (IMTX)May 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 5, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Increase Earnings Estimates for Immatics (NASDAQ:IMTX)May 3, 2023 | msn.comImmatics (IMTX) Moves 27.5% Higher: Will This Strength Last?May 2, 2023 | finance.yahoo.comWhat's Going On With Immatics Shares TodayMay 2, 2023 | markets.businessinsider.comUS Stocks Down; Chegg Crashes After Removing Guidance On ChatGPT ConcernsMay 2, 2023 | msn.comImmatics climbs 30% after early Phase 1 data for solid tumor therapyMay 2, 2023 | msn.comImmatics Soars after Positive Clinical UpdateMay 2, 2023 | finance.yahoo.comImmatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMEMay 1, 2023 | markets.businessinsider.comBristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New CollaborationApril 20, 2023 | americanbankingnews.comHead to Head Review: Entera Bio (NASDAQ:ENTX) & Immatics (NASDAQ:IMTX)April 19, 2023 | americanbankingnews.comImmatics (NASDAQ:IMTX) Trading 7.1% Higher April 16, 2023 | finance.yahoo.comImmatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 42% of the companyApril 8, 2023 | barrons.comImmatics N.V.April 5, 2023 | americanbankingnews.comImmatics (NASDAQ:IMTX) Sees Unusually-High Trading VolumeApril 1, 2023 | nasdaq.comMizuho Initiates Coverage of Immatics (IMTX) with Buy RecommendationMarch 31, 2023 | msn.comImmatics initiated Buy at Mizuho on underrated TCR opportunityMarch 31, 2023 | americanbankingnews.comImmatics (NASDAQ:IMTX) Coverage Initiated by Analysts at MizuhoMarch 30, 2023 | markets.businessinsider.comImmatics (IMTX) Initiated with a Buy at Mizuho SecuritiesMarch 29, 2023 | americanbankingnews.comImmatics (NASDAQ:IMTX) Trading 5.2% Higher See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Company Calendar Last Earnings3/21/2023Today5/29/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees188Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.75 High Stock Price Forecast$26.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+100.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$39.53 million Net Margins-85.93% Pretax Margin-88.57% Return on Equity-41.31% Return on Assets-17.89% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual Sales$182.13 million Price / Sales4.15 Cash Flow$0.61 per share Price / Cash Flow16.11 Book Value$2.93 per share Price / Book3.36Miscellaneous Outstanding Shares76,670,000Free FloatN/AMarket Cap$755.20 million OptionableNot Optionable Beta0.44 Key ExecutivesDr. Harpreet Singh Ph.D. (Age 47)CEO, MD, Member of Management Board & Supervisory Director Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardDr. Toni Weinschenk Ph.D. (Age 49)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 56)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 46)Chief Technology Officer Mr. Edward A. SturchioGen. Counsel & Sec.Ms. Anja Heuer B.Sc.Director of Corp. CommunicationsMs. Tamara Louw M.B.A.P.H.R., Sr. Director of HRDr. Carsten Reinhardt M.D. (Age 55)Ph.D., Chief Devel. Officer Dr. Rainer Kramer Ph.D. (Age 57)Chief Bus. Officer & Site Head Munich More ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLNovavaxNASDAQ:NVAXEditas MedicineNASDAQ:EDITTwist BioscienceNASDAQ:TWSTAlectorNASDAQ:ALECView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Sold 53,603 shares on 5/18/2023Ownership: 0.294%Governors Lane LPSold 17,527 shares on 5/16/2023Ownership: 0.170%State Street CorpBought 33,456 shares on 5/16/2023Ownership: 0.044%Jane Street Group LLCBought 18,385 shares on 5/16/2023Ownership: 0.024%Squarepoint Ops LLCBought 16,240 shares on 5/16/2023Ownership: 0.021%View All Institutional Transactions IMTX Stock - Frequently Asked Questions Should I buy or sell Immatics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. What is Immatics' stock price forecast for 2023? 4 brokerages have issued 1-year price targets for Immatics' stock. Their IMTX share price forecasts range from $12.00 to $26.00. On average, they expect the company's stock price to reach $19.75 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price. View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts. How have IMTX shares performed in 2023? Immatics' stock was trading at $8.71 at the beginning of the year. Since then, IMTX shares have increased by 13.1% and is now trading at $9.85. View the best growth stocks for 2023 here. Are investors shorting Immatics? Immatics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,420,000 shares, an increase of 28.1% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 370,900 shares, the short-interest ratio is presently 11.9 days. Currently, 8.1% of the company's shares are sold short. View Immatics' Short Interest. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) posted its earnings results on Tuesday, March, 21st. The company reported ($0.23) EPS for the quarter. The business earned $38.44 million during the quarter, compared to analysts' expectations of $13.18 million. Immatics had a negative net margin of 85.93% and a negative trailing twelve-month return on equity of 41.31%. What ETFs hold Immatics' stock? ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). What is Immatics' stock symbol? Immatics trades on the NASDAQ under the ticker symbol "IMTX." Who are Immatics' major shareholders? Immatics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.87%), Price T Rowe Associates Inc. MD (0.77%), Braidwell LP (0.42%), JPMorgan Chase & Co. (0.29%), Hudson Bay Capital Management LP (0.28%) and Governors Lane LP (0.17%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immatics' stock price today? One share of IMTX stock can currently be purchased for approximately $9.85. How much money does Immatics make? Immatics (NASDAQ:IMTX) has a market capitalization of $755.20 million and generates $182.13 million in revenue each year. The company earns $39.53 million in net income (profit) each year or ($1.06) on an earnings per share basis. How many employees does Immatics have? The company employs 188 workers across the globe. How can I contact Immatics? Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 4.97072E+12. This page (NASDAQ:IMTX) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.